Sign In
Buy INBX
$95.22
+1.59 (+1.70%)
At Close: Jun 03, 2026
Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much
04:41pm, Thursday, 17'th Aug 2023
INBX is researching a breakthrough for Alpha-1 Antitrypsin deficiency and has received regulatory support for its INBRX-101 pipeline. The AATD treatment market is expected to experience robust growth
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
04:00pm, Monday, 07'th Aug 2023
SAN DIEGO , Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipel
Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage
09:40am, Tuesday, 27'th Jun 2023
A Chinese developer of cutting-edge cancer drugs has accused a chief competitor of stealing its trade secrets by posing as an expert witness in an arbitration hearing as a way of surreptitiously getti
Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates
07:45pm, Monday, 08'th May 2023
Inhibrx, Inc. (INBX) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.80 per share a year ago.
Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength?
03:49am, Thursday, 04'th May 2023
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa
Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Monday, 06'th Mar 2023
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -18.75% and 8.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx Announces Participation in Upcoming Investor Conference
04:05pm, Friday, 18'th Nov 2022
SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today an
Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates
07:35pm, Monday, 07'th Nov 2022
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 10.89% and 60.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Is Inhibrx (INBX) Stock Soaring 45% Today?
03:33pm, Tuesday, 04'th Oct 2022
Following a rough outing throughout much of this year, biopharmaceutical firm Inhibrx (NASDAQ: INBX ) finally gave stakeholders reason to smile. Earlier today, the company announced it discussed with
Biotech Stock Soars on Potential FDA Fast-Track
01:58pm, Tuesday, 04'th Oct 2022
The shares of Inhibrix Inc (NASDAQ:INBX) are soaring today, up 41.1% at $28.48 at last glance, after the company alluded to potentially accelerated U.S. Food & Drug Administration (FDA) approval of it
Inhibrx, Inc. (INBX) Reports Q2 Loss, Lags Revenue Estimates
09:04pm, Monday, 08'th Aug 2022
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -15.48% and 21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Reports Q1 Loss, Misses Revenue Estimates
08:18pm, Monday, 09'th May 2022
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of -29.03% and 7.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates
09:15pm, Thursday, 05'th May 2022 Zacks Investment Research
KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of 34.69% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
10:32am, Tuesday, 03'rd May 2022 Zacks Investment Research
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
08:17am, Tuesday, 03'rd May 2022
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa
